Top View
- Cutaneous Vasculopathy As an Adverse Effect of the Anti–Vascular
- Cancer Drug Costs for a Month of Treatment at Initial Food
- Pathway for the Acute Myeloid Leukemia Treatment
- Novel Drugs for Older Patients with Acute Myeloid Leukemia
- Personalized Medicine Tumour Vs Patient Profile Etienne GC Brain, MD Phd Medical Oncology Hôpital René Huguenin / Institut Curie Saint-Cloud, France
- Intracranial Regression of an Advanced Basal Cell Carcinoma Using Sonidegib and Itraconazole After Failure with Vismodegib Jaeyoung Yoon Forefront Dermatology
- (Vismodegib) for Gleevec
- The Surgeon General's Call to Action to Prevent Skin Cancer
- ERIVEDGE (Vismodegib) Capsule Can Result in Embryo-Fetal Death Or Severe Birth Defects
- Pharmacology Update
- The Anti-Angiogenic Compound Axitinib Demonstrates Low Toxicity and Anti-Tumoral Effects Against Medulloblastoma
- A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature
- Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Effective: August 16, 2021
- Efficacy and Safety of Sonic Hedgehog Pathway Inhibitors in Cancer
- U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, Or Metastatic Basal Cell Carcinoma
- Threshold of Toxicological Concern (TTC) for Anticancer Compounds
- Hedgehog Signaling Inhibators and Their Importance for Cancer Treatment
- Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
- OPCW, Scientific Advisory Board
- Outpatient Cancer Drug Benefit Program List
- Vismodegib for Recurrent, Locally Advanced Or Metastatic Basal Cell Carcinoma Mich
- Diapositiva 1
- WO 2016/004043 Al O O©
- Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome
- Mypathway Study: a Novel Precision Oncology Multiple Basket Trial
- The London School of Economics and Political Science Cancer Medicines
- Reimbursement Criteria for Frequently Requested Drugs
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- 203388Orig1s000
- Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib
- Risk Assessment and Risk Mitigation Review(S)
- Policy Drug(S) Brief Description of Policy Change Add Inclusion Criteria: NOTE: the Preferred Dose of Jevtana for NCH Policy Is 20 Mg/M2, IV, Every 3 Weeks
- New Advances and Challenges of Targeting Cancer Stem Cells Nurmaa K
- Targeting the Autophagy Promoted Antitumor Effect of T-DM1 on HER2
- Nilotinib, an Approved Leukemia Drug, Inhibits Smoothened Signaling in Hedgehog- Dependent Medulloblastoma
- I, Paolo Antonio Ascierto
- Targeted Therapies in the Treatment of Advanced Basal Cell Carcinoma Michael R
- PRECISION MEDICINE at the INFLECTION POINT Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC
- Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma Shalini V
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- WO 2017/136652 Al 10 August 2017 (10.08.2017) P O P C T
- Top Notch Targeting Strategies in Cancer: a Detailed Overview of Recent Insights and Current Perspectives
- ERIVEDGE Prescribing Information
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
- Nilotinib, an Approved Leukemia Drug, Inhibits Smoothened Signaling In
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Vandetanib (Caprelsa®) Abbreviated National Drug Monograph May 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- Phase 2 Study of Vismodegib, a Hedgehog Inhibitor, Combined with Gemcitabine and Nab-Paclitaxel in Patients with Untreated Metastatic Pancreatic Adenocarcinoma
- Oncology Oral, Skin Cancer Therapeutic Class Review
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- New Treatment Options for Acute Myeloid Leukemia in 2019
- Oncology Oral Medications Enrollment Form
- Availability of Evidence of Benefits on Overall Survival and Quality of Life Of
- Emetogenic Potential of Antineoplastic Agents
- 210656Orig1s000
- Learningpharmacology 2018.Pdf
- Hedgehog Signaling Inhibition in the Treatment of Basal Cell Carcinoma
- Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated with Brentuximab Vedotin
- Update NCI-MATCH Trial, Patient-Derived Models Repository